For every indication proven in the pre-clinical st

For every indication proven in the pre-clinical studies that Leronlimab works we can immediately go to the Phase II trial due to a long-term research conducted over 700 people. Leronlimab will probably be approved for 6-7 months and we will be the first in the market with a safe CCR5 antagonist. After Phase II for mTNBC and 8 pre-clinical studies for other cancers we will go with a basket study which will include multiple cancers and prove the MOA for Leronlimab. We will be the first to do this with a CCR5 antagonist who will already be approved on the market at the same time. That's the most interesting thing for me.